Skip to content

Efficacy Study of Multimodal Computer Vision-Assisted Diagnosis for Antipsychotic-Induced Tardive Dyskinesia

Efficacy Study of Multimodal Computer Vision-Assisted Diagnosis for Antipsychotic-Induced Tardive Dyskinesia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107681
Enrollment
Unknown
Registered
2025-08-18
Start date
2025-08-20
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tardive Dyskinesia

Interventions

Gold Standard:Diagnostic criteria for "tardive dyskinesia" in the fifth edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-V)
Index test:Microsoft Kinect2 device was used to collect the speech, RGB video, infrared features and depth information of patients with tardigrade dyskinesia. The facial and/or limb movement features

Sponsors

The First Affiliated Hospital of the Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Previous mental illness; 2. Taking antipsychotic drugs; 3. Meet the diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V) "tardive dyskinesia" diagnostic criteria; 4. Aged between 18 and 60 years old; 5. Voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Other diseases that may cause involuntary movement: drug-induced acute dystonia, tic disorders, Parkinsonism, etc. 2. suffering from the following serious diseases: history of brain trauma or cerebrovascular accident, narrow Angle glaucoma, epilepsy, myocardial infarction, unstable angina pectoris, congestive heart failure, severe liver cirrhosis, acute and chronic renal failure, severe diabetes mellitus, aplastic anemia, moderate to severe malnutrition and other serious nervous, heart, liver, kidney, endocrine, blood system and other serious physical diseases; 3. Have an intracranial mass, cerebral infarction, increased intracranial pressure, or other active central nervous system disease, including epilepsy, dementia, delirium, amnesia, or other cognitive disease; 4. Substance abuse (excluding caffeine and nicotine) in the past 3 months; 5. Those who are at high risk of suicide, or who have committed suicide or serious self-harm and need urgent intervention; 6. Refusal to sign informed consent; 7. Known to have serious adverse reactions to the study process, refused or could not cooperate to complete the study process.

Design outcomes

Primary

MeasureTime frame
Accuracy;Pricision; Specificity;Recall;F1 score;Receiver Operating Characteristic Curve,ROC;Area Under Curve,AUC;Abnormal Involuntary Movement Scale, AIMS;

Secondary

MeasureTime frame
Tardive Dyskinesia Rating Scale, TDRS;TD Impact Scale;Rating Scale for Extrapyramidal Side Effects. RSESE;Treatment Emergent Symptom Scale;UKU Side Effects Scale;

Countries

China

Contacts

Public ContactCai Yanhui

The First Affiliated Hospital of the Air Force Military Medical University

MD_CAI@163.com+86 182 2086 5143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026